Histone deacetylase inhibitors and anticancer therapy

Area of Science:

• Epigenetics
• Cancer Pharmacology
• Chromatin Biology

Background:

• Histone deacetylase (HDAC) inhibitors modulate chromatin remodeling, impacting gene transcription.
• Aberrant histone acetylation is linked to dysregulation of cell cycle, differentiation, and apoptosis pathways in cancer.
• Dimethyl sulfoxide was an early identified inducer of transformed cell differentiation.

Purpose of the Study:

• To review the potential of histone deacetylase (HDAC) inhibitors as a cancer treatment strategy.
• To highlight various classes and examples of HDAC inhibitors.
• To discuss the clinical implications and future directions for HDAC inhibitor therapy.

Main Methods:

• Review of recent reports and clinical studies on HDAC inhibitors.
• Categorization of HDAC inhibitors by chemical class (e.g., short-chain fatty acids, hydroxamic acids, cyclic tetrapeptides, benzamides).
• Analysis of safety and efficacy data from early clinical trials.

Main Results:

• HDAC inhibitors represent a promising class of anticancer agents.
• Clinical studies demonstrate that histone hyperacetylation can be safely achieved in humans.
• Various HDAC inhibitors, including SAHA, trichostatin A, and MS-275, are under investigation.

Conclusions:

• Pharmacological manipulation of chromatin remodeling via HDAC inhibitors offers a potent strategy for cancer treatment.
• HDAC inhibitors are emerging as a significant class of novel anticancer agents.
• Further studies are required to determine optimal dosing, duration, and synergistic combinations for HDAC inhibitor therapy.